Результаты поиска - Peter D. Eisenberg

  • Отображение 1 - 14 результаты of 14
Отмена результатов
  1. 1
    Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study

    Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study по Peter D. Eisenberg, F. Roy MacKintosh, Paul S. Ritch, Patricia A. Cornett, A. Macciocchi

    Опубликовано 2004
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT<sub>3</sub> receptor antagonist

    Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT<sub>3</sub> receptor antagonist по Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora, Veena Charu, Julio Hajdenberg, Alan Cartmell, A. Macciocchi, Steven M. Grunberg

    Опубликовано 2003
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer

    Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer по Anthony Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl G. Kardinal, Alan F. Cohen, Joe Schulz, Peter D. Eisenberg, John Forster, Paul Wissel

    Опубликовано 2009
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

    Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion по Lee S. Rosen, David Gordon, William Dugan, Pierre Major, Peter D. Eisenberg, Louise Provencher, Mary Kaminski, J. Simeone, John J. Seaman, Bee‐Lian Chen, Robert E. Coleman

    Опубликовано 2003
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

    A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors по David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Šikić

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design

    Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design по Daniel V.T. Catenacci, Anteneh Tesfaye, M.A. Tejani, Eric Cheung, Peter D. Eisenberg, Aaron J. Scott, Clarence Eng, James Hnatyszyn, Neyssa Marina, Janine Powers, Zev A. Wainberg

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

    Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy по Jørn Herrstedt, Hyman B. Muss, David Warr, Paul J. Hesketh, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodgers, Carolyn M. Hustad, Kevin Horgan, Franck Skobieranda

    Опубликовано 2005
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines по Denis Talbot, Vladimir Moiseyenko, Simon Van Belle, S.M. O'Reilly, Emilio Alba, Stephen P. Ackland, Peter D. Eisenberg, David Melnychuk, Tadeusz Pieńkowski, H-U Burger, Siobhan Laws, B Osterwalder

    Опубликовано 2002
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

    Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced,... по Daniel D. Karp, Luis Paz‐Ares, Silvia Novello, Paul Haluska, Linda L. Garland, Felipe Cardenal, L. Johnetta Blakely, Peter D. Eisenberg, Corey J. Langer, George R. Blumenschein, Faye M. Johnson, Stephanie Green, Antonio Gualberto

    Опубликовано 2009
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane по Harold J. Burstein, Anthony Elias, Hope S. Rugo, Melody A. Cobleigh, Antonio C. Wolff, Peter D. Eisenberg, Mary Jo Lehman, Bonne J. Adams, Carlo L. Bello, Samuel E. DePrimo, Charles M. Baum, Kathy D. Miller

    Опубликовано 2008
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

    Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy по David Warr, Paul J. Hesketh, Richard J. Gralla, Hyman B. Muss, Jørn Herrstedt, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodgers, Norman R. Bohidar, George Klinger, Carolyn M. Hustad, Kevin Horgan, Franck Skobieranda

    Опубликовано 2005
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

    Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial по Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak, Minesh P. Mehta, James Liebmann, Tim Illidge, Ian Kunkler, J. Caudrelier, Peter D. Eisenberg, J.H. Meerwaldt, Ross Siemers, C. Carrié, Laurie E. Gaspar, Walter J. Curran, S. Phan, Richard Miller, Markus F. Renschler

    Опубликовано 2003
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

    Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin по Daniel D. Karp, Michaël Pollak, Roger B. Cohen, Peter D. Eisenberg, Paul Haluska, Donghua Yin, Allan Lipton, Laurence M. Demers, Kim Leitzel, Mary L. Hixon, Leon W.M.M. Terstappen, Linda L. Garland, Luis Paz‐Ares, Felipe Cardenal, Corey J. Langer, Antonio Gualberto

    Опубликовано 2009
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma по Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan

    Опубликовано 2012
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: